deltatrials
Unknown PHASE1 INTERVENTIONAL 1-arm NCT05495035

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Study for Safety and Efficacy Evaluation of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (R/R Ph + ALL）

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Conditions Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Lymphoblastic Leukemia, Acute, Childhood Refractory Leukemia Relapsed Leukemia
Interventions Olverembatinib, APG-2575, Dexamethasone
Updated 6 times since 2022 Last updated: Mar 1, 2023 Started: Sep 1, 2022 Primary completion: Aug 31, 2024 Completion: Dec 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Leukemia, Lymphoblastic, Acute, Philadelphia-Positive and Lymphoblastic Leukemia, Acute, Childhood, this trial is ongoing. The trial is conducted by Institute of Hematology & Blood Diseases Hospital, China and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshotNot Yet Recruiting~Apr 2023 – ~Oct 2023 · 6 months · monthly snapshotRecruiting~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshotRecruiting~Jan 2025 – present · 18 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Jan 2025 — Present [monthly]

    Unknown PHASE1

    Status: Recruiting → Unknown

  2. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Oct 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

  5. Apr 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. Sep 2022 — Apr 2023 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institute of Hematology & Blood Diseases Hospital, China
Data source: Institute of Hematology & Blood Diseases Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations